17 Aug Amphotericin B – Risk of Medication Error
Posted at 13:01h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA) Bristol-Myers Squibb and Key Oncologies (Ply) Ltd would like to draw your attention to the risk of errors in prescribing, dispensing, preparing and administering different parenteral formulations of amphotericin B.
2019 Apr
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
10/04/2019
File Type:
pdf
Category:
Communication To Health Care Professionals